testosterone 4-n-butylcyclohexylcarboxylic acid: testosterone ester which maintains serum testosterone of castrated monkeys in normal range for 4 months [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 114819 |
| SCHEMBL ID | 3361905 |
| SCHEMBL ID | 10394704 |
| MeSH ID | M0143744 |
| Synonym |
|---|
| testosterone buciclate |
| [(8r,9s,10r,13s,14s,17s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 4-butylcyclohexane-1-carboxylate |
| testosterone 4-n-butylcyclohexylcarboxylate |
| 20 aet-1 |
| 17beta-(((trans-4-butylcyclohexyl)carbonyl)oxy)androst-4-en-3-one |
| 20-aet-1 |
| testosterone 4-n-butylcyclohexylcarboxylic acid |
| 105165-22-8 |
| androst-4-en-3-one, 17-(((trans-4-butylcyclohexyl)carbonyl)oxy)-, (17beta)- |
| androst-4-en-3-one, 17-(((4-butylcyclohexyl)carbonyl)oxy)-, (17beta(trans))- |
| 39BV4XZ2CW |
| testosterone bucyclate |
| SCHEMBL3361905 |
| SCHEMBL10394704 |
| Q27256882 |
| DTXSID90909371 |
| AKOS040756528 |
| 118931-19-4 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " The suppression of testicular and epididymal functions by TB indicates that this long-acting androgen may have the potentiality to induce and maintain reversible sterility, but further evaluation needs to be carried out to develop an appropriate dosage regimen that would prevent return to normal functions in order to develop this long-acting androgen as a hormonal male contraceptive." | ( Effects of testosterone buciclate on testicular and epididymal sperm functions in bonnet monkeys (Macaca radiata) Bajaj, JS; Kinger, S; Kumar, PK; Pal, PC; Rajalakshmi, M; Sharma, DN, 1995) | 0.29 |
| " Dose-response increases to peak levels of levonorgestrel were attained on day 7 in groups V, VI and VII, after the first injection." | ( Evaluation of the ability of levonorgestrel butanoate alone, or in combination with testosterone buciclate, to suppress spermatogenesis in the bonnet monkey (Macaca radiata). Griffin, PD; Jeyaraj, DA; Pal, PC; Rajalakshmi, M; Sharma, RS; Waites, GM, 2000) | 0.31 |
| " The present data clearly indicate that administration of CPA and TB in proper dosage combination can provide an effective, safe, and reversible method of male contraception." | ( Evaluation of efficacy, safety, and reversibility of combination regimen of cyproterone acetate and testosterone buciclate in bonnet monkey. Behal, VK; Chaturvedi, PK; Pal, PC; Pruthi, JS; Rajalakshmi, M; Roy, S; Sharma, DN; Sharma, RS, 2000) | 0.31 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (12.50) | 18.7374 |
| 1990's | 14 (58.33) | 18.2507 |
| 2000's | 6 (25.00) | 29.6817 |
| 2010's | 1 (4.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.53) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 3 (12.00%) | 5.53% |
| Reviews | 2 (8.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 20 (80.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||